ASCO-Update 2006 - Neuigkeiten vom 42. Meeting der American Society of Clinical Oncology/ASCO 2006

A. Reinacher-Schick; D. Arnold; F. Lordick; M. Möhler; M. P. Lutz; T. Seufferlein

doi:10.1055/s-2006-927142

Zeitschrift für Gastroenterologie, Inhaltsverzeichnis

Z Gastroenterol 2006; 44(10): 1065-1072
DOI: 10.1055/s-2006-927142

Übersicht

ASCO-Update 2006 - Neuigkeiten vom 42. Meeting der American Society of Clinical Oncology/ASCO 2006

ASCO Update 2006 - Highlights of the 42. Meeting of the American Society of Clinical Oncology/ASCO 2006A. Reinacher-Schick¹ , D. Arnold² , F. Lordick³ , M. Möhler⁴ , M. P. Lutz⁵ , T. Seufferlein⁶ [*] ¹

¹Medizinische Universitätsklinik, Knappschaftskrankenhaus, Ruhr-Universität Bochum
²Klinik für Innere Medizin IV, Universität Halle
³III. Medizinische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München
⁴I. Medizinische Klinik und Poliklinik, Universität Mainz
⁵Medizinische Klinik, Caritasklinik St. Theresia, Saarbrücken
⁶Klinik für Innere Medizin I, Universitätsklinikum Ulm

Abstract

Zusammenfassung

Kaum ein Gebiet der Gastroenterologie hat sich in den letzten Jahren so schnell entwickelt wie die Therapie gastrointestinaler Tumoren, nicht zuletzt durch den Einsatz von Targeted Therapies. Wir möchten Ihnen in der folgenden Übersicht wie bereits im vergangenen Jahr [22] die wichtigsten neuen klinischen Studien zu Ösophagus-, Magen-, kolorektalen, Pankreas-, Leber- und Gallenwegskarzinomen vorstellen und bewerten, die auf dem diesjährigen Meeting der American Society of Clinical Oncology präsentiert wurden.

Abstract

Currently, the treatment of gastrointestinal cancers is rapidly changing due to the implementation of novel chemotherapeutic agents as well as the introduction of targeted therapies into treatment protocols. The following review will give an overview on the most important clinical trials in esophageal, gastric, colorectal, pancreatic and hepatobiliary cancer that were presented at the annual meeting of the American Society of Clinical Oncology.

Schlüsselwörter

Ösophaguskarzinom - Magenkarzinom - kolorektales Karzinom - Pankreaskarzinom - Leberzellkarzinom - Gallenwegskarzinom - Targeted Therapies - klinische Studien

Key words

esophageal cancer - gastric cancer - colorectal cancer - pancreatic cancer - hepatobiliary cancer - targeted therapies - clinical trials

Volltext

Referenzen

Literatur
(Angegeben sind jeweils die Nummern der Abstracts, die unter www.asco.org eingesehen werden können)

1 Al-Batran S. et al . A randomized phase III trial in patients with advanced adenocarcinoma of the stomach receiving first-line chemotherapy with fluorouracil, leucovorin and oxaliplatin (FLO) versus fluorouracil, leucovorin and cisplatin (FLP). JCO. 2006; 24 (18S) LBA4016
2 Arnold D. et al . , Phase I/II study of cetuximab, capecitabine and oxaliplatin (CAPOX) combined with standard radiotherapy (RTX) as neoadjuvant treatment of advanced rectal cancer (RC). JCO. 2006; 24 (18S) A3574
3 Bosset J F. et al . Preoperative radiation (Preop RT) in rectal cancer: effect and timing of additional chemotherapy (CT) 5-year results of the EORTC 22 921 trial. JCO. 2005; 23 A3505
4 Carr B I. et al . Gemcitabine hepatic arterial chemoembolization (TACE) in the treatment of unresectable HCC. JCO. 2006; 24 (18S) A4141
5 Cassidy J. et al . Randomized double blind (DB) placebo (Plcb) controlled phase III study assessing the efficacy of xaliproden (X) in reducing the cumulative peripheral sensory neuropathy (PSN) induced by the oxaliplatin (Ox) and 5-FU/LV combination (FOLFOX4) in first-line treatment of patients (pts) with metastatic colorectal cancer (MCRC). JCO. 2006; 24 (18S) A3507
6 Chauffert C. et al . Phase III trial comparing initial chemoradiotherapy (intermittent cisplatin and infusional 5-FU) followed by gemcitabine vs. gemcitabine alone in patients with locally advanced non metastatic pancreatic cancer: A FFCD-SFRO study. JCO. 2006; 24 (18S) A4008
7 Chung K Y. et al . Phase I trial of preoperative cetuximab with concurrent continuous infusion 5-fluorouracil and pelvic radiation in patients with local-regionally advanced rectal cancer. JCO. 2006; 24 (18S) A3560
8 Cohn A. et al . Single-agent pemetrexed in patients with advanced and metastatic hepatoma. JCO. 2006; 24 (18S) A14064
9 Cunningham D. et al . Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer. New England Journal of Medicine. 2006; 355 11-20
10 Cunningham D. et al . Randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: The REAL 2 trial. JCO. 2006; 24 (18S) LBA4017
11 Czito B G. et al . Preliminary results of a phase I study of external beam radiation therapy (EBRT), oxaliplatin (OX), bevacizumab (BV), and capecitabine (CAP) for locally advanced or metastatic adenocarcinoma of the rectum. JCO. 2006; 24 (18S) A3543
12 Di Fabio F. et al . 18FDG-PET in targeted therapy with cetuximab in gastric or gastroesophageal junction (GEJ) adenocarcinoma: First results of the Italian FOLCETUX Study. JCO. 2006; 24 (18S) A4061
13 Eckel F. et al . Chemotherapy in advanced biliary tract carcinoma (BTC): A comprehensive analysis. JCO. 2006; 24 (18S) A14036
14 Feisthammel J. et al . Irinotecan with 5-FU/FA in advanced biliary tract adenocarcinoma - a two-center phase II trial (GBFiri). JCO. 2006; 24 (18S) A14088
15 Fiorica F. et al . Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut. 2004; 53 925-930
16 Fuchs C. et al . A randomized trial of first-line irinotecan/fluoropymidine combinations with or without celecoxib in metastatic colorectal cancer (BICC-C). JCO. 2006; 24 (18S) A 3506
17 Gerard J, Bonnetain F, Conroy T. et al . Preoperative (preop) radiotherapy (RT) + 5 FU/folinic acid (FA) in T3 - 4 rectal cancers: results of the FFCD 9203 randomized trial. JCO. 2005; 23 A3504
18 Greer S E. et al . Neoadjuvant chemoradiotherapy for esophageal carcinoma: a meta-analysis. Surgery. 2005; 137 172-177
19 Harder J. et al . Outpatient chemotherapy with gemcitabine and oxaliplatin in advanced biliary tract cancer; a phase II study. JCO. 2006; 24 (18S) A14006
20 Heinemann V. et al . Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. JCO. 2006; 24 3946-3952
21 Hochster H S. et al . Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): Final analysis of the TREE-Study. JCO. 2006; 24 (18S) A3510
22 Hohler T. et al . ASCO-Update 2005 - Highlights of the 41st Meeting of the American Society of Clinical Oncology/ASCO 2005. Z Gastroenterol. 2005; 43 1253-1259
23 Igbal S. et al . A phase II trial of gemcitabine and capecitabine in patients (pts) with unresectable or metastatic gallbladder cancer or cholangiocarcinoma. JCO. 2006; 24 (18S) A4134
24 Kang Y. et al . Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC): Efficacy and safety results. JCO. 2006; 24 (18S) LBA4018
25 Kawamoto T. et al . Amplification of HER-2/neu (erb2) gene expression in gallbladder (GBC) and in bile duct cancer (BDC) (biliary tract cancer, BTC). JCO. 2006; 24 (18S) A4011
26 Kindler H L. et al . A randomized phase II study of bevacizumab (B) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis. JCO. 2006; 24 (18S) A4040
27 Knox J J. et al . A phase II trial of oblimersen sodium (G3139) in combination with docorubicin (DOX) in advanced hepatocellular carcinoma (HCC). NCI protocol # 5789. JCO. 2006; 24 (18S) A14072
28 Ko A H. et al . A phase II study of gemcitabine (GEM) given at fixed-dose rate (FDR) infusion, low-dose cisplatin (CDDP), and bevacizumab in metastatic pancreatic cancer (PanCa). JCO. 2006; 24 (18S) A4041
29 Labianca R. et al . Alternating versus continuous „FOLFIRI” in advanced colorectal cancer (ACC): A randomized „GISCAD” trial. JCO. 2006; 24 (18S) A3505
30 Lin C. et al . Arsenic trioxide in patients with hepatocellular carcinoma: A phase II trial. JCO. 2006; 24 (18S) A14129
31 Machiels J P. et al . Phase I study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer. JCO. 2006; 24 (18S) A3552
32 Maindrault-Goebel F. et al . OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC). A GERCOR study. JCO. 2006; 24 (18S) A3504
33 Marijnen C. et al . Long term results, toxicity and quality of life in the TME trial. ASCO Gastrointestinal Cancers Symposium. 2006; A166
34 Moehler M. et al . Irinotecan/capecitabine versus cisplatin/capecitabine in advanced adenocarcinoma of the stomach or gastroesophageal junction: Interim analysis of a randomized German AIO phase II study. JCO. 2006; 24 (18S) A4032
35 Moore M J. et al . Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). JCO. 2005; 23 A1
36 Morinaga S. et al . Expression of Epidermal growth factor receptor (EGFR) associates with proliferation, apoptosis, and histologically aggressive features in hepatocellular carcinoma. JCO. 2006; 24 (18S) A14039
37 Nehls O. et al . A prospective multicenter phase II trial of capecitabine plus oxaliplatin (CapOx) in advanced biliary system adenocarcinomas: The final results. JCO. 2006; 24 (18S) A4136
38 Neuhaus P, Oettle H, Post S. et al . A randomised, prospective, multicenter, phase III trial of adjuvant chemotherapy with gemcitabine vs. observation in patients with resected pancreatic cancer. JCO. 2005; 23 A4013
39 Nordlinger P. et al . Complete radiological response of colorectal liver metastases (LM) chemotherapy: Does it mean cure?. JCO. 2006; 24 (18S) A3501
40 O’Dwyer P J. et al . Gefitinib in advanced unresectable hepatocellular carcinoma: Results from the Eastern Cooperative Oncology Group’s Study E1203. JCO. 2006; 24 (18S) A4143
41 Poplin E. et al . Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion[FDR]) versus gemcitabine + oxaliplatin(GEMOX) in patients with advanced pancreatic cancer (E6201). JCO. 2006; 24 (18S) LBA4004
42 Qin SK. et al . Preliminary results of a phase II trial of FOLFOX4 regimen in Chinese patients with unresectable primary liver cancer. JCO. 2006; 24 (18S) A14065
43 Quirke P. et al . Local recurrence after rectal cancer resection is strongly related to the plane of surgical dissection and is further reduced by pre-operative short course radiotherapy. Preliminary results of the Medical Research Council (MRC) CR07 trial. JCO. 2006; 24 (18S) A3512
44 Ramanathan R K. et al . Phase II study of lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase 1 and 2 (Her2/Neu) in patients (pts) with advanced biliary tree cancer (BTC) or hepatocellular cancer (HCC). A California Consortium (CCC-P) Trial. JCO. 2006; 24 (18S) A4010
45 Regine W F. et al . RTOG 9704a phase III study of adjuvant pre and post chemoradiation (CRT) 5-FU vs. gemcitabine (G) for resected pancreatic adenocarcinoma. JCO. 2006; 24 (18S) A4007
46 Richards D A. et al . Phase II multicenter trial of docetaxel+oxaliplatin in stage IV gastroesophageal and/or stomach cancer. JCO. 2006; 24 (18S) A4071
47 Rizk N P. et al . Impact of pre-operative chemoradiotherapy on post-esophagectomy morbidity and mortality. JCO. 2006; 24 (18S) A4025
48 Roedel K. et al . Multicenter phase II trial of preoperative radiotherapy with concurrent and adjuvant capecitabine and oxaliplatin in locally advanced rectal cancer. ASCO Gastrointestinal Cancer Symposium. 2006; A349
49 Sauer R. et al . Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004; 351 1731-1740
50 Schwartz J D. et al . Bevacizumab in unresectable hepatocellular carcinoma (HCC) for patients without metastasis and without invasion of the portal vein. JCO. 2006; 24 (18S) A4144
51 Sebag-Montefiore D. et al . Routine short course pre-op radiotherapy or selective post-op chemoradiotherapy for resectable rectal cancer? Preliminary results of the MRC CR07 randomised trial. JCO. 2006; 24 (18S) A3511
52 Shah M A. et al . Final results of a multicenter phase II study of irinotecan (CPT), cisplatin (CIS), and bevacizumab (BEV) in patients with metastatic gastric or gastroesophageal (GEJ) adenocarcinoma (NCI #6447). JCO. 2006; 24 (18S) A4020
53 Sharma A. et al . Gemcitabine and oxaliplatin (Gemox) in advanced/unresectable gall bladder cancer: A phase II study. JCO. 2006; 24 (18S) A14027
54 Siegel A B. et al . Current treatments, determinants of use, and survival for patients with hepatoma in the United States from 1998 - 2002. JCO. 2006; 24 (18S) A4138
55 Stahl M, Stuschke M, Lehmann N. et al . Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. JCO. 2005; 23 2310-2317
56 Tebbutt N. et al . Randomised phase II study evaluating weekly docetaxel in combination with cisplatin and 5FU or capecitabine in metastatic oesophago-gastric cancer. JCO. 2006; 24 (18S) A4067
57 Tepper J E. et al . Superiority of trimodality therapy to surgery alone in esophageal cancer: results of CALGB 9781. JCO. 2006; 24 A 4012
58 Urschel J D. et al . A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg. 2003; 185 538-543
59 Venook A. et al . Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80 203 preliminary results. JCO. 2006; 24 (18S) A3509
60 Willett C G. et al . Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004; 10 145-147
61 Yu S C. et al . Transarterial ethanol ablation of unresectable hepatocellular carcinoma with lipiodol-ethanol mixture (LEM): A phase II study. JCO. 2006; 24 (18S) A14054
62 Yu J. et al . A randomized clinical study of surgery versus radiotherapy in the treatment of resectable esophageal cancer. JCO. 2006; 24 (18S) A4013
63 Zhu A X. et al . Phase II study of cetuximab in patients with unresectable or metastatic hepatocellular carcinoma. JCO. 2006; 24 (18S) A14096

1 für die Arbeitsgemeinschaft Gastroenterologische Onkologie der DGVS.

Thomas Seufferlein

Klinik für Innere Medizin I, Universitätsklinikum Ulm

Robert-Koch-Str. 8

89081 Ulm

eMail: thomas.seufferlein@uniklinik-ulm.de